Y-mAbs Therapeutics, Inc. (YMAB) Covered Calls
You can sell covered calls on Y-mAbs Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for YMAB (prices last updated Wed 4:16 PM ET):
| Y-mAbs Therapeutics, Inc. (YMAB) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 8.78 | -0.75 | 5.00 | 11.27 | 357K | - | 0.4 |
| Covered Calls For Y-mAbs Therapeutics, Inc. (YMAB) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 10 | 0.00 | 11.27 | -11.3% | -1374.8% | |
| Jan 17 | 10 | 0.00 | 11.27 | -11.3% | -133.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | EEM covered calls | 1. | NVDA covered calls | |
| 2. | SPY covered calls | 7. | IWM covered calls | 2. | RGTI covered calls | |
| 3. | XLF covered calls | 8. | KWEB covered calls | 3. | QUBT covered calls | |
| 4. | QQQ covered calls | 9. | TLT covered calls | 4. | MU covered calls | |
| 5. | FXI covered calls | 10. | TSLA covered calls | 5. | QBTS covered calls | |
Want more examples? YLD Covered Calls | YOLO Covered Calls
